摘要 |
Disclosed are compounds of the formula I or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein each variable in Formula 1 are as defined in the specification; and pharmaceutical compositions comprising the compounds of formula I. Also disclosed are methods of inhibiting aspartyl protease, and in particular, the methods of treating cardiovascular diseases, cognitive and neurodegenerative diseases, and the methods of inhibiting of Human Immunodeficiency Virus, plasmepins, cathepsin D and protozoal enzymes. Also disclosed are methods of treating cognitive or neurodegenerative diseases using the compounds of formula I in combination with a cholinesterase inhibitor or a muscarinic m1 agonist or m2 antagonist. |
申请人 |
ZHU ZHAONING;MCKITTRICK BRIAN;SUN ZHONG-YUE;YE YUANZAN C.;VOIGHT JOHANNES H.;STRICKLAND COREY O.;SMITH ELIZABETH M.;STAMFORD ANDREW;GREENLEE WILLIAM J.;MAZZOLA ROBERT D.;CALDWELL JOHN P.;CUMMING JARED N.;WANG LINGYAN;WU YUSHENG;ISERLOH ULRICH;LIU XIAOXIANG;GUO TAO;LE THUY X.E.;SAIONZ KURT W.;BABU SURESH D.;HUNTER RACHAEL C.;MORRIS MICHELLE L.;GU HUIZHONG;QIAN GANG;TADESSE DAWIT;HUANG YING;LI GUOQING;PAN JIANPING;MISIASZEK JEFFREY A.;LAI GAIFA;DUO JINGQI;QU CHUANXING;SHAO YUEFEI;PHARMACOPEIA INC.;SCHERING CORPORATION |
发明人 |
ZHU ZHAONING;MCKITTRICK BRIAN;SUN ZHONG-YUE;YE YUANZAN C.;VOIGHT JOHANNES H.;STRICKLAND COREY O.;SMITH ELIZABETH M.;STAMFORD ANDREW;GREENLEE WILLIAM J.;MAZZOLA ROBERT D.;CALDWELL JOHN P.;CUMMING JARED N.;WANG LINGYAN;WU YUSHENG;ISERLOH ULRICH;LIU XIAOXIANG;GUO TAO;LE THUY X.E.;SAIONZ KURT W.;BABU SURESH D.;HUNTER RACHAEL C.;MORRIS MICHELLE L.;GU HUIZHONG;QIAN GANG;TADESSE DAWIT;HUANG YING;LI GUOQING;PAN JIANPING;MISIASZEK JEFFREY A.;LAI GAIFA;DUO JINGQI;QU CHUANXING;SHAO YUEFEI |